Aptose Biosciences Inc Cash Flow Conversion Efficiency
Aptose Biosciences Inc cash flow conversion efficiency. Based on the latest financial reports, Aptose Biosciences Inc (APS) has a cash flow conversion efficiency ratio of 0.381x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$-7.41 Million ≈ $-5.36 Million USD) by net assets (CA$-19.45 Million ≈ $-14.07 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Aptose Biosciences Inc (1996–2024)
Cash flow conversion efficiency of Aptose Biosciences Inc from 1996 to 2024. This chart illustrates how Aptose Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Aptose Biosciences Inc for real-time trading data and today's change.
Aptose Biosciences Inc Cash Flow Conversion Ratio Explained
Aptose Biosciences Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Aptose Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aptose Biosciences Inc ranked by their cash flow conversion efficiency. Also see Aptose Biosciences Inc (APS) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PDZ Holdings Bhd
KLSE:6254
|
0.132x |
|
AUX Resources Corporation
V:AUX
|
-0.300x |
|
Triton Minerals Ltd
AU:TON
|
-0.084x |
|
Northern Shield Resources Inc.
V:NRN
|
0.004x |
|
Ronin Resources Ltd
AU:RON
|
-0.059x |
|
Marston’s PLC
LSE:MARS
|
0.029x |
|
Blue Ocean Acquisition Corp
NASDAQ:BOCN
|
-0.078x |
|
Jackpot Digital Inc
V:JJ
|
0.170x |
Annual Cash Flow Conversion Efficiency for Aptose Biosciences Inc (1996–2024)
The table below shows the annual cash flow conversion efficiency of Aptose Biosciences Inc from 1996 to 2024. Review Aptose Biosciences Inc free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$-4.54 Million ≈ $-3.29 Million |
CA$-35.98 Million ≈ $-26.03 Million |
7.919x | -48.48% |
| 2023-12-31 | CA$-2.90 Million ≈ $-2.10 Million |
CA$-44.59 Million ≈ $-32.26 Million |
15.371x | +1894.75% |
| 2022-12-31 | CA$37.74 Million ≈ $27.30 Million |
CA$-32.32 Million ≈ $-23.38 Million |
-0.856x | -46.82% |
| 2021-12-31 | CA$74.24 Million ≈ $53.70 Million |
CA$-43.30 Million ≈ $-31.33 Million |
-0.583x | -104.68% |
| 2020-12-31 | CA$118.92 Million ≈ $86.02 Million |
CA$-33.89 Million ≈ $-24.52 Million |
-0.285x | -24.17% |
| 2019-12-31 | CA$93.93 Million ≈ $67.94 Million |
CA$-21.56 Million ≈ $-15.59 Million |
-0.230x | +86.07% |
| 2018-12-31 | CA$14.08 Million ≈ $10.19 Million |
CA$-23.21 Million ≈ $-16.79 Million |
-1.648x | -64.47% |
| 2017-12-31 | CA$10.20 Million ≈ $7.38 Million |
CA$-10.22 Million ≈ $-7.40 Million |
-1.002x | +39.69% |
| 2016-12-31 | CA$7.33 Million ≈ $5.30 Million |
CA$-12.17 Million ≈ $-8.81 Million |
-1.661x | -129.30% |
| 2015-12-31 | CA$13.65 Million ≈ $9.87 Million |
CA$-9.89 Million ≈ $-7.15 Million |
-0.725x | -84.19% |
| 2014-12-31 | CA$25.28 Million ≈ $18.28 Million |
CA$-9.94 Million ≈ $-7.19 Million |
-0.393x | -106.04% |
| 2013-12-31 | CA$-757.75K ≈ $-548.15K |
CA$-4.94 Million ≈ $-3.57 Million |
6.516x | +296.38% |
| 2012-12-31 | CA$-1.95 Million ≈ $-1.41 Million |
CA$-3.21 Million ≈ $-2.32 Million |
1.644x | +106.67% |
| 2011-12-31 | CA$244.66K ≈ $176.99K |
CA$-6.03 Million ≈ $-4.36 Million |
-24.661x | -459.21% |
| 2010-12-31 | CA$-513.68K ≈ $-371.59K |
CA$-3.53 Million ≈ $-2.55 Million |
6.865x | +694.85% |
| 2009-12-31 | CA$-7.66 Million ≈ $-5.54 Million |
CA$-6.62 Million ≈ $-4.79 Million |
0.864x | -67.36% |
| 2008-12-31 | CA$-3.87 Million ≈ $-2.80 Million |
CA$-10.25 Million ≈ $-7.42 Million |
2.646x | +131.98% |
| 2007-12-31 | CA$711.16K ≈ $514.45K |
CA$-5.88 Million ≈ $-4.26 Million |
-8.274x | -261.85% |
| 2006-12-31 | CA$-2.32 Million ≈ $-1.68 Million |
CA$-11.87 Million ≈ $-8.58 Million |
5.112x | +462.25% |
| 2005-12-31 | CA$10.57 Million ≈ $7.65 Million |
CA$-14.92 Million ≈ $-10.79 Million |
-1.411x | 0.00% |
| 2004-12-31 | CA$10.57 Million ≈ $7.65 Million |
CA$-14.92 Million ≈ $-10.79 Million |
-1.411x | -43.83% |
| 2003-12-31 | CA$20.99 Million ≈ $15.19 Million |
CA$-20.60 Million ≈ $-14.90 Million |
-0.981x | -263.72% |
| 2002-12-31 | CA$28.89 Million ≈ $20.90 Million |
CA$-7.79 Million ≈ $-5.64 Million |
-0.270x | 0.00% |
| 2001-12-31 | CA$28.89 Million ≈ $20.90 Million |
CA$-7.79 Million ≈ $-5.64 Million |
-0.270x | -56.21% |
| 2000-12-31 | CA$36.38 Million ≈ $26.32 Million |
CA$-6.28 Million ≈ $-4.55 Million |
-0.173x | -121.46% |
| 1999-12-31 | CA$45.89 Million ≈ $33.19 Million |
CA$-3.58 Million ≈ $-2.59 Million |
-0.078x | +95.88% |
| 1998-12-31 | CA$1.29 Million ≈ $932.14K |
CA$-2.44 Million ≈ $-1.77 Million |
-1.895x | -106.70% |
| 1997-12-31 | CA$3.30 Million ≈ $2.38 Million |
CA$-3.02 Million ≈ $-2.19 Million |
-0.917x | -141.90% |
| 1996-12-31 | CA$6.89 Million ≈ $4.99 Million |
CA$-2.61 Million ≈ $-1.89 Million |
-0.379x | -- |
About Aptose Biosciences Inc
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloi… Read more